ExThera Medical & Fresenius Medical Care Sign Distribution Agreement for Seraph 100 Blood Purification Device in Mexico
Feb 3, 2022

Seraph 100 used for Blood Purification and Pathogen Reduction in Sepsis and COVID-19 Treatments

MARTINEZ, Calif. – ExThera Medical and Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, announced the expanded distribution of ExThera’s Seraph® 100 Microbind® Affinity Blood Filter in Mexico. In 2021, ExThera Medical and Fresenius Medical Care partnered to distribute the Seraph 100® in select European countries.

The Seraph 100 is used in intensive care medicine for the reduction of pathogens in the blood and can be operated with Fresenius Medical Care acute dialysis machines. Similar to a dialysis procedure, the blood is purified through extracorporeal equipment, but Seraph 100 uniquely captures circulating pathogens from the bloodstream; adsorbed pathogens include a myriad of infectious agents, including SARS-CoV-2, MRSA and even super-resistant bacteria.

“ExThera’s growing partnership with Fresenius Medical Care allows more critically ill patients access to a treatment for broad pathogen-oriented shock, including COVID-19, at a crucial time when cases are spiking and hospitals are overwhelmed,” said Robert Ward, ExThera Medical Chairman and CEO.

“We need every tool available in Mexico as new variants will no doubt continue to put a burden on hospitals working tirelessly to deliver life-saving care to patients with COVID-19,” said Alfredo Merino, President of Fresenius Medical Care Mexico. “As experts in extracorporeal therapy, we are excited to help deliver this new filter to improve treatment for people impacted by a range of bacterial and viral infections.”

The Seraph 100 has been used to treat more than 800 COVID-19 patients, in over 70 hospitals, globally. Early results have demonstrated reduced mortality and reduced ICU length of stay in severe/critically ill COVID-19 patients in preliminary clinical studies1,2. The device received European CE mark in 2019 for the for the reduction of bloodstream pathogens, and was granted Emergency Use Authorization (EUA) by the FDA in 2020 for use in patients with COVID-19 admitted to the ICU with confirmed or imminent respiratory failure.

1) Chitty et al, A Multicenter Evaluation of Blood Purification with Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19: A Preliminary Report, (2021)
2) Schmidt et al, Interim-analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry, NDT, 2021; gfab347


About Fresenius Medical Care
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 3.7 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,151 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

About ExThera Medical Corporation
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter for removing a broad range of pathogens from the bloodstream of patients. Seraph can be used in hospitals, clinics, or field hospitals to address nosocomial and community-acquired infections as well as those caused by battlefield wounds and pandemics. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis and other severe infections. With a growing body of outcome and health economic evidence from independent clinical studies, success in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the US, the EU, and the Middle East, the company is well positioned to serve healthcare professionals and patients alike. The Seraph 100® is CE marked and commercially available in the EU and has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA.

For more information visit the company’s website at www.extheramedical.com.

About Seraph 100®
As a patient’s blood flows through the Seraph 100 filter, it passes over beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis.

For more news stories on the Seraph 100 click here.

All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.

MM0006 Rev B